Ionis Pharmaceuticals, Inc. (LON:0JDI)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 3.69B -60.2% |
| Revenue (ttm) | 723.17M -0.7% |
| Net Income | -411.67M |
| EPS | -2.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,369 |
| Open | 31.51 |
| Previous Close | 30.48 |
| Day's Range | 28.08 - 31.98 |
| 52-Week Range | 27.85 - 86.74 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ... [Read more]
Financial Performance
In 2025, Ionis Pharmaceuticals's revenue was $943.71 million, an increase of 33.83% compared to the previous year's $705.14 million. Losses were -$381.39 million, -15.97% less than in 2024.
Financial numbers in USD Financial StatementsNews
Ionis Pharmaceuticals price target lowered to $60 from $87 at Piper Sandler
Piper Sandler lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $87 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals price target lowered to $80 from $95 at Wells Fargo
Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $95 and keeps an Overweight rating on the shares. Tryngolza launch was more…
Ionis Pharmaceuticals price target lowered to $70 from $100 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $100 and keeps a Buy rating on the shares post the Q3 report.
Ionis Pharmaceuticals price target lowered to $41 from $58 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $41 from $58 and keeps a Neutral rating on the shares. Ionis faces near-term specialty cardiovascular launch headwinds…
Ionis Pharmaceuticals price target lowered to $63 from $91 at BofA
BofA lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $63 from $91 and keeps a Buy rating on the shares. While it is “not a surprise” that Ionis…
Ionis Pharmaceuticals price target lowered to $72 from $85 at Canaccord
Canaccord lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $72 from $85 and keeps a Buy rating on the shares. The firm said 3Q had overall top-/bottom-line beats,…
Ionis Pharmaceuticals price target lowered to $81 from $88 at UBS
UBS lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $81 from $88 and keeps a Buy rating on the shares. Tryngolza sales significantly missed expectations, prompting a 50%…
Ionis Pharmaceuticals price target lowered to $70 from $85 at Oppenheimer
Oppenheimer analyst Justin Kim lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $85 and keeps an Outperform rating on the shares. The firm notes the company…
Ionis Pharmaceuticals price target lowered to $53 from $84 at TD Cowen
TD Cowen lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $53 from $84 and keeps a Buy rating on the shares. The firm said Tryngolza is off to…
Ionis Pharmaceuticals price target lowered to $75 from $104 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $75 from $104 and keeps an Overweight rating on the shares.
Ionis Pharmaceuticals price target lowered to $60 from $85 at RBC Capital
RBC Capital lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $85 and keeps an Outperform rating on the shares. The company’s Q3 result was a disappointing…
Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a com...
IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals
Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to TRYNGOLZ...
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Bioph...
Ionis Pharmaceuticals falls -27.3%
Ionis Pharmaceuticals (IONS) is down -27.3%, or -$10.75 to $28.67.
Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating
Kehoe Law Firm investigating potential securities claims on behalf of Ionis (IONS) investors following reduced TRYNGOLZA sales guidance and stock decline
Ionis Pharmaceuticals falls -27.0%
Ionis Pharmaceuticals (IONS) is down -27.0%, or -$10.64 to $28.78.
Ionis Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue grew 55% YoY excluding the prior-year sapablursen payment, while commercial growth was led by DAWNZERA. TRYNGOLZA’s slower launch lowered 2026 sales guidance, but pipeline approvals and readouts added growth opportunities.
Ionis Pharmaceuticals Earnings release: Q3 2026
Ionis Pharmaceuticals released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Ionis Pharmaceuticals Quarterly report: Q3 2026
Ionis Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 9, 2026.
Ionis Pharmaceuticals Slides: Q3 2026
Ionis Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 9, 2026.
A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings
Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
Ionis Pharmaceuticals reports Q3 EPS (66c), consensus (93c)
Reports Q3 revenue $243M, consensus $184.38M. “In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class m...
Ionis Pharmaceuticals sees FY26 revenue $875M-$900M, consensus $922.37M
Sees FY26 cash, cash equivalents, and short-term investments above $1.6B